martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom

View original at nasdaq.com
“TSMC anticipates its operating profit margin to be 57.5% in Q2 (at the midpoint of its guidance range).”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia anticipates $1 trillion in AI data center chip sales in 2026 and 2027

    60% confidence
  • Broadcom sees $100 billion in AI chip revenue in fiscal 2027, up from $20 billion in fiscal 2025

    60% confidence
  • TSMC anticipates operating profit margin of 57.5% in Q2 2026 at the midpoint of guidance range

    60% confidence
  • TSMC expects revenue to increase by more than 30% in 2026, revised from earlier forecast of close to 30%

    60% confidence
  • TSMC could be the ultimate pick-and-shovel AI stock for 2026 and beyond due to its wider reach in AI chips than Nvidia and Broadcom

    60% confidence
  • Stock Advisor's total average return is 994%, outperforming the S&P 500's 199%

    60% confidence
  • TSMC forecasts 32% year-over-year revenue increase in Q2 2026 to $39.6 billion

    60% confidence
  • TSMC is expected to continue raising prices for its advanced chip nodes over the next four years

    60% confidence

Data points we hold from this source

Taiwan Semiconductor Manufacturing Company · forward earnings multiple25 ratio
Taiwan Semiconductor Manufacturing Company · net profit margin50.5 percent
Taiwan Semiconductor Manufacturing Company · eps3.49 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com